The only study evaluating the therapeutic effects of anti-CTLA-4 (ipilimumab) in combination with anti-PD-1 (nivolumab) in advanced AM showed an ORR of 42.9%, a 1-year PFS rate of 43%, and a 1-year OS rate of 86%, which were all much higher than those of anti-CTLA-4 or anti-PD-1 immunotherapy alone, demonstrating that administering nivolumab plus ipilimumab may provide a more hopeful treatment choice for patients with AM than either agent alone. This evidence concerns the gene CTLA4 and acute myeloblastic leukemia with maturation.